Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. Repligen’s corporate headquarters are located in Waltham, MA, USA; we have an additional manufacturing facility in Lund, Sweden.
Company growth
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
168 (est)+24%
Repligen was founded in 1981 and is headquartered in Waltham, US

Key People at Repligen

Walter C. Herlihy

Walter C. Herlihy

President and CEO
William J. Kelly

William J. Kelly

CFO
Greg Zarbis-Papastoitsis

Greg Zarbis-Papastoitsis

Team Member

Repligen Office Locations

Repligen has offices in Waltham, Lund
Waltham, US
Lund, SE

Repligen Metrics

Repligen Summary

Market capitalization

$1.09 B

Closing share price

$32.4
Repligen's current market capitalization is $1.09 B.

Repligen Financials

Repligen's revenue is $83.5 M in FY, 2015 which is 31.45% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$83.5 M$63.5 M$68.2 M

Revenue growth, %

31.5%-6.8%

Gross profit

$48.3 M$35.5 M$45.7 M

Operating income

$13.8 M$10.7 M$22.9 M

Operating expense total

$34.5 M$24.8 M$22.8 M

Net Income

$9.35 M$8.17 M$16.1 M

Operating cash flow

$18.7 M$-4.47 M$10.6 M

Repligen Market Value History

Repligen Online Presence

Repligen Company Life

You may also be interested in